OR WAIT null SECS
© 2023 MJH Life Sciences™ and Applied Clinical Trials Online. All rights reserved.
Applied Clinical Trials
Cathleen Dohrn, Senior Scientific Director for Continuum Clinical, describes the momentous challenges in clinical trials presented by low awareness of nonalcoholic steatohepatitis.
Nonalcoholic steatohepatitis (NASH) is a form of nonalcoholic fatty liver disease (NAFLD) that remains largely unknown among the adult population in the U.S. In the coming years, however, prevalence of this potentially deadly disease, which can lead to cirrhosis and even liver cancer, is expected to grow significantly. According to a 2018 study2, instances of NASH in the United States are expected to increase 63% from 16.52 million to 27.00 million cases by 2030.
The complications associated with NASH include cirrhosis and liver cancer, with an increased chance of dying from liver-related causes. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK3), studies have shown that people with NAFLD have a greater chance of developing cardiovascular disease-the most common cause of death among people with NAFLD or NASH.
To highlight the seriousness of NASH, there currently exists no FDA-approved therapy to treat the disease. In the next five years, more than 60 sponsors4 will attempt to randomize nearly 30,000 NASH patients into clinical trials. So pharmaceutical companies face an uphill battle to both increase awareness of this deadly disease and enroll tens of thousands of patients in NASH clinical trials.
Of all of the challenges that sponsors face in enrolling patients into NASH studies, the biggest is lack of awareness of the disease even among patients most at-risk-those with type 2 diabetes, obesity, and hypertension.
Continuum Clinical conducted a survey of 1,014 adults in the U.S. and found only 2% were aware of NASH. A follow-up study of 450 adults with comorbidities associated with NASH revealed only 6% were aware of the disease.
Continuum also found that 48% of at-risk Hispanic/Latino respondents were most concerned about liver disease versus 32% of the total population surveyed. In addition, Hispanic/Latino respondents were significantly more interested in learning about a hypothetical NASH clinical research study (62% versus 49% of the total population.)
In addition to low awareness of NASH, targeting patients for clinical trials is challenging because the disease doesn’t manifest itself in consistent, overt ways. Many times, patients with NASH are asymptomatic.
Right now, it’s estimated that as many as 30 million Americans have NASH, but only 180,000 have been diagnosed. Given the average participation rate in clinical trials is around 15% of a given diagnosed population-and coupled with an 80% screen/fail rate in this condition-that means the 180,000 patients will translate into only 3,000 randomizations.
The FDA currently requires sponsor protocols to confirm patients’ NASH diagnosis via an invasive and potentially dangerous liver biopsy.
In order for progress to be made against this disease, pharmaceutical companies must find solutions to some of the problems posed above. Where are pharmaceutical companies to begin? How does a drug company reach out to consumers who aren’t aware of a disease that they may or may not have to enroll in a clinical trial that requires a liver biopsy for a diagnosis?
The FDA issued a guidance5 in December, which urges the pharmaceutical industry to develop/validate better biomarkers for NASH diagnosis and progression. In many regards, getting over the biopsy hurdle rivals lack of general awareness of NASH, which is why we believe it is important for pharmaceutical companies to invest in innovations (e.g. a variety of imaging techniques) to allay this patient burden, and subsequently persuade the FDA with strong data to accept those innovations as suitable endpoint markers for clinical trials. To that end, many researchers are investigating such biomarkers that will be as predictive, if not more so, than invasive liver biopsies.1
This long-term solution doesn’t help the number of trials enrolling now, however. Addressing the gap between the diagnosed patient population and the number of patients who will be needed to fill these trials requires implementing a robust patient recruitment program.
Sponsors with designs on this therapeutic area could consider increased investment in developing unbranded disease awareness campaigns alongside patient advocacy groups; the National Liver Foundation has begun to do such an educational campaign on their own. In addition to these education efforts, incorporating fundamental disease education into clinical trial recruitment outreach materials is critical. This is unusual but not unheard of-Continuum has in the past successfully included IRB-approved education information for an unaware patient audience for a different chronic disease campaign.
In conjunction with a broad-based disease education plan, smart web development-for example, a site that funnels disease-aware or diagnosed patients to a different landing page than unaware or undiagnosed patients-will be necessary to motivate potential patients to complete study screening.
Specific to this are materials that target patient demographics that are disproportionately affected by NASH or NAFLD, such as Hispanic and Latino patients. Directly engaging patients locally through educational and community events is critical to connect with patients both before and after diagnosis. Community-level engagement, especially important to populations typically underrepresented in clinical research, will ensure NASH patients receive education and information at the right time in their journey and can make recruitment campaigns more effective.
Despite the potentially enormous patient population, the challenges industry will face in enrolling clinical trials are daunting and unique. NASH patients are diverse, both ethnically and in their diagnostic pathway. The only way to successfully achieve the required trial enrollment numbers is to be strategic, creative, and thorough in planning both for recruitment and retention.
Cathleen Dohrn, PhD is the Senior Scientific Director, Continuum Clinical.